Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
Naim Alkhouri, MD, chief medical officer, chief of transplant hepatology, and director of the fatty liver program at Arizona Liver Health, in Phoenix, said that he and fellow researchers investigating treatments for metabolic dysfunction-associated liver disease, or MASLD, and metabolic dysfunction-associated steatohepatitis, or MASH, have their work cut out for them for a decade, at least. In a recent interview with Patient Care® Alkhouri offered a topline review of molecules currently moving through phase 2 and phase 3 clinical trials.
Other videos in this series with Dr Alkhouri:
A MASLD Mantra to Practice By: Screen, Stage, Treat
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
Related Content
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025Article
The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
